Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 29 | 2022 | 107 | 5.250 |
Why?
|
| Antidepressive Agents | 26 | 2023 | 100 | 3.610 |
Why?
|
| Depressive Disorder | 29 | 2007 | 187 | 2.840 |
Why?
|
| Bipolar Disorder | 14 | 2017 | 127 | 2.280 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 6 | 2023 | 8 | 2.140 |
Why?
|
| Antidepressive Agents, Second-Generation | 12 | 2010 | 25 | 1.230 |
Why?
|
| Psychiatric Status Rating Scales | 25 | 2020 | 343 | 1.170 |
Why?
|
| Ketamine | 2 | 2023 | 33 | 1.040 |
Why?
|
| Fluoxetine | 15 | 2009 | 33 | 1.020 |
Why?
|
| Antipsychotic Agents | 9 | 2016 | 82 | 1.010 |
Why?
|
| Secondary Prevention | 16 | 2020 | 64 | 0.920 |
Why?
|
| Double-Blind Method | 29 | 2020 | 503 | 0.890 |
Why?
|
| Vagus Nerve Stimulation | 2 | 2022 | 7 | 0.810 |
Why?
|
| Tetrahydrofolates | 3 | 2016 | 3 | 0.810 |
Why?
|
| Valproic Acid | 5 | 2008 | 30 | 0.780 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2003 | 36 | 0.770 |
Why?
|
| Depression | 7 | 2022 | 466 | 0.730 |
Why?
|
| Treatment Outcome | 33 | 2022 | 3476 | 0.730 |
Why?
|
| Triazoles | 6 | 2003 | 30 | 0.690 |
Why?
|
| Cyclohexanols | 9 | 2010 | 18 | 0.670 |
Why?
|
| Humans | 77 | 2023 | 29361 | 0.670 |
Why?
|
| Drug Therapy, Combination | 15 | 2019 | 241 | 0.640 |
Why?
|
| Suicidal Ideation | 1 | 2017 | 5 | 0.600 |
Why?
|
| Adult | 44 | 2019 | 8604 | 0.580 |
Why?
|
| Male | 55 | 2020 | 15637 | 0.550 |
Why?
|
| Female | 53 | 2020 | 16211 | 0.530 |
Why?
|
| Middle Aged | 36 | 2020 | 9823 | 0.520 |
Why?
|
| Electroconvulsive Therapy | 3 | 2017 | 15 | 0.490 |
Why?
|
| Piperazines | 10 | 2015 | 90 | 0.480 |
Why?
|
| Folic Acid | 2 | 2016 | 16 | 0.440 |
Why?
|
| Anxiety Disorders | 4 | 2002 | 168 | 0.420 |
Why?
|
| Drug Administration Schedule | 15 | 2007 | 223 | 0.400 |
Why?
|
| Sexual Dysfunctions, Psychological | 4 | 2005 | 10 | 0.380 |
Why?
|
| Acetamides | 1 | 2010 | 7 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 437 | 0.360 |
Why?
|
| Pirenzepine | 3 | 2003 | 6 | 0.340 |
Why?
|
| Adolescent | 13 | 2015 | 2280 | 0.310 |
Why?
|
| Personality Inventory | 5 | 2012 | 72 | 0.300 |
Why?
|
| Acute Disease | 7 | 2013 | 226 | 0.300 |
Why?
|
| Antimanic Agents | 1 | 2006 | 10 | 0.300 |
Why?
|
| Social Adjustment | 2 | 2010 | 28 | 0.280 |
Why?
|
| Administration, Intranasal | 2 | 2023 | 26 | 0.270 |
Why?
|
| Sertraline | 5 | 2006 | 19 | 0.260 |
Why?
|
| Aged | 17 | 2016 | 9447 | 0.260 |
Why?
|
| Remission Induction | 5 | 2020 | 96 | 0.250 |
Why?
|
| Venlafaxine Hydrochloride | 9 | 2010 | 17 | 0.240 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 1184 | 0.240 |
Why?
|
| Obsessive-Compulsive Disorder | 4 | 2006 | 23 | 0.240 |
Why?
|
| Placebos | 7 | 2006 | 77 | 0.240 |
Why?
|
| Prospective Studies | 4 | 2017 | 1812 | 0.230 |
Why?
|
| Obesity | 3 | 2015 | 290 | 0.230 |
Why?
|
| Recurrence | 5 | 2016 | 350 | 0.220 |
Why?
|
| Ambulatory Care | 7 | 2008 | 75 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 1829 | 0.210 |
Why?
|
| Young Adult | 5 | 2016 | 1935 | 0.210 |
Why?
|
| Chronic Disease | 5 | 2017 | 495 | 0.200 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 3 | 0.190 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 14 | 0.180 |
Why?
|
| Pyrrolidines | 1 | 2020 | 21 | 0.180 |
Why?
|
| Benzamides | 1 | 2020 | 16 | 0.180 |
Why?
|
| Quality of Life | 5 | 2010 | 664 | 0.180 |
Why?
|
| Patient Compliance | 5 | 2007 | 164 | 0.170 |
Why?
|
| Psychotic Disorders | 2 | 2001 | 43 | 0.160 |
Why?
|
| Long-Term Care | 2 | 2016 | 58 | 0.160 |
Why?
|
| Thiazoles | 2 | 2012 | 35 | 0.160 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2004 | 23 | 0.160 |
Why?
|
| C-Reactive Protein | 2 | 2015 | 125 | 0.150 |
Why?
|
| Severity of Illness Index | 6 | 2007 | 1113 | 0.150 |
Why?
|
| Phenethylamines | 1 | 2016 | 5 | 0.150 |
Why?
|
| Pyridines | 1 | 2016 | 42 | 0.140 |
Why?
|
| Sexual Behavior | 1 | 1997 | 66 | 0.140 |
Why?
|
| Comorbidity | 6 | 2015 | 497 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 364 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 340 | 0.140 |
Why?
|
| Glutamates | 1 | 2015 | 17 | 0.140 |
Why?
|
| Registries | 1 | 2017 | 189 | 0.140 |
Why?
|
| Serotonin | 2 | 1997 | 40 | 0.140 |
Why?
|
| Dizziness | 4 | 2007 | 20 | 0.130 |
Why?
|
| Psychometrics | 5 | 2012 | 262 | 0.130 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2007 | 4 | 0.130 |
Why?
|
| Hypericum | 2 | 2005 | 3 | 0.130 |
Why?
|
| Paroxetine | 4 | 2007 | 14 | 0.130 |
Why?
|
| Phytotherapy | 2 | 2005 | 15 | 0.130 |
Why?
|
| Sulfides | 1 | 2015 | 12 | 0.130 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 38 | 0.130 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2014 | 1 | 0.130 |
Why?
|
| Aldehydes | 1 | 2014 | 2 | 0.130 |
Why?
|
| S-Adenosylmethionine | 1 | 2014 | 6 | 0.130 |
Why?
|
| Administration, Oral | 2 | 2019 | 140 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2000 | 58 | 0.120 |
Why?
|
| Vagus Nerve | 2 | 2022 | 14 | 0.120 |
Why?
|
| Nausea | 3 | 1999 | 27 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 389 | 0.120 |
Why?
|
| Inflammation | 1 | 2015 | 345 | 0.120 |
Why?
|
| Anticonvulsants | 2 | 2003 | 109 | 0.110 |
Why?
|
| Tranylcypromine | 1 | 1991 | 1 | 0.110 |
Why?
|
| Hypertension | 2 | 2007 | 266 | 0.100 |
Why?
|
| Prevalence | 1 | 2013 | 491 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 75 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2005 | 788 | 0.100 |
Why?
|
| Headache | 3 | 2007 | 43 | 0.100 |
Why?
|
| Orgasm | 1 | 1991 | 9 | 0.100 |
Why?
|
| Patient Education as Topic | 3 | 2003 | 162 | 0.100 |
Why?
|
| Fever | 1 | 1991 | 40 | 0.100 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2015 | 10 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2010 | 56 | 0.090 |
Why?
|
| Patient Selection | 1 | 2011 | 232 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2010 | 140 | 0.090 |
Why?
|
| Tachyphylaxis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Delayed-Action Preparations | 4 | 2010 | 38 | 0.080 |
Why?
|
| Benzodiazepines | 3 | 2003 | 60 | 0.080 |
Why?
|
| Sleep Stages | 2 | 1999 | 34 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2015 | 1010 | 0.080 |
Why?
|
| 1-Naphthylamine | 2 | 1997 | 4 | 0.080 |
Why?
|
| Half-Life | 2 | 1997 | 18 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 32 | 0.070 |
Why?
|
| Serotonin Antagonists | 2 | 2001 | 19 | 0.070 |
Why?
|
| Syndrome | 2 | 1997 | 82 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 66 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2004 | 8 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2010 | 321 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 78 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2007 | 132 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 104 | 0.070 |
Why?
|
| Weight Gain | 3 | 2001 | 66 | 0.070 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 44 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2007 | 3273 | 0.060 |
Why?
|
| Thiophenes | 1 | 2004 | 13 | 0.060 |
Why?
|
| Morpholines | 1 | 2003 | 14 | 0.060 |
Why?
|
| Psychotherapy | 1 | 2003 | 34 | 0.060 |
Why?
|
| Drug Tolerance | 1 | 2002 | 12 | 0.060 |
Why?
|
| Health Status | 3 | 2003 | 227 | 0.060 |
Why?
|
| Body Weight | 2 | 2002 | 133 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2003 | 56 | 0.050 |
Why?
|
| Biomarkers | 2 | 2015 | 692 | 0.050 |
Why?
|
| Drug Interactions | 2 | 1991 | 67 | 0.050 |
Why?
|
| Mianserin | 1 | 2001 | 15 | 0.050 |
Why?
|
| Buspirone | 1 | 2001 | 6 | 0.050 |
Why?
|
| Bupropion | 1 | 2001 | 7 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 9 | 0.050 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 14 | 0.050 |
Why?
|
| Sulfones | 1 | 2001 | 24 | 0.050 |
Why?
|
| Sexuality | 1 | 2001 | 18 | 0.050 |
Why?
|
| Telephone | 1 | 2000 | 27 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2001 | 52 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2000 | 9 | 0.050 |
Why?
|
| Purines | 1 | 2001 | 32 | 0.050 |
Why?
|
| Asthenia | 1 | 2000 | 1 | 0.050 |
Why?
|
| Desipramine | 1 | 2000 | 6 | 0.050 |
Why?
|
| Feeding and Eating Disorders | 1 | 2000 | 12 | 0.050 |
Why?
|
| Nasal Sprays | 1 | 2019 | 3 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2000 | 75 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 333 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2000 | 97 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 553 | 0.040 |
Why?
|
| Drug Synergism | 2 | 1995 | 63 | 0.040 |
Why?
|
| Anxiety | 1 | 1999 | 152 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1997 | 2 | 0.040 |
Why?
|
| MEDLINE | 1 | 1997 | 5 | 0.040 |
Why?
|
| Prognosis | 1 | 2000 | 840 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 1997 | 13 | 0.040 |
Why?
|
| Abbreviations as Topic | 1 | 1997 | 1 | 0.040 |
Why?
|
| Paresthesia | 1 | 1997 | 6 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 1997 | 13 | 0.040 |
Why?
|
| Receptors, Serotonin | 1 | 1997 | 21 | 0.040 |
Why?
|
| Norepinephrine | 1 | 1997 | 19 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 20 | 0.040 |
Why?
|
| Life Change Events | 1 | 1997 | 36 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1997 | 24 | 0.040 |
Why?
|
| Medical Records | 1 | 1997 | 29 | 0.040 |
Why?
|
| Quetiapine Fumarate | 1 | 2016 | 2 | 0.040 |
Why?
|
| Triazines | 1 | 2016 | 10 | 0.040 |
Why?
|
| Time Factors | 3 | 2010 | 1618 | 0.040 |
Why?
|
| Down-Regulation | 1 | 1997 | 112 | 0.040 |
Why?
|
| Imipramine | 1 | 1996 | 13 | 0.030 |
Why?
|
| Community Mental Health Services | 1 | 1996 | 12 | 0.030 |
Why?
|
| Family Practice | 1 | 1996 | 20 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2006 | 55 | 0.030 |
Why?
|
| Adiponectin | 1 | 2015 | 9 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 1995 | 11 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 22 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1997 | 324 | 0.030 |
Why?
|
| Infant | 1 | 1997 | 531 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1997 | 140 | 0.030 |
Why?
|
| Primary Health Care | 1 | 1997 | 95 | 0.030 |
Why?
|
| Plant Extracts | 2 | 2005 | 16 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 1997 | 604 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 108 | 0.030 |
Why?
|
| Affect | 1 | 1995 | 64 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1995 | 48 | 0.030 |
Why?
|
| Phobic Disorders | 1 | 1995 | 62 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 215 | 0.030 |
Why?
|
| Incidence | 1 | 1997 | 756 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1995 | 126 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 1995 | 87 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1993 | 13 | 0.030 |
Why?
|
| Lithium | 1 | 1993 | 23 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 405 | 0.030 |
Why?
|
| Child | 1 | 1997 | 1345 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 75 | 0.030 |
Why?
|
| Amitriptyline | 1 | 1991 | 4 | 0.030 |
Why?
|
| Sympathomimetics | 1 | 1991 | 8 | 0.030 |
Why?
|
| Pemoline | 1 | 1991 | 2 | 0.030 |
Why?
|
| Dextroamphetamine | 1 | 1991 | 6 | 0.030 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1991 | 20 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 1991 | 26 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1251 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1990 | 8 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 118 | 0.020 |
Why?
|
| Risk Factors | 1 | 1997 | 2446 | 0.020 |
Why?
|
| Hospitalization | 1 | 1991 | 317 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 162 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2007 | 52 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2007 | 22 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 43 | 0.020 |
Why?
|
| Outpatients | 1 | 2007 | 52 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 145 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1442 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2005 | 28 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2005 | 31 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 227 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2007 | 246 | 0.020 |
Why?
|
| Sex Factors | 1 | 2005 | 496 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2003 | 5 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 638 | 0.010 |
Why?
|
| United States | 1 | 2010 | 2332 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 78 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 9 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 298 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 70 | 0.010 |
Why?
|
| Priapism | 1 | 2002 | 10 | 0.010 |
Why?
|
| Suicide | 1 | 2002 | 14 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2001 | 27 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 87 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2001 | 11 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2001 | 66 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2001 | 25 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 159 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2001 | 78 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 295 | 0.010 |
Why?
|
| Appetite | 1 | 1999 | 5 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 845 | 0.010 |
Why?
|
| Weight Loss | 1 | 1999 | 98 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1999 | 427 | 0.010 |
Why?
|